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Technologies allowing for the derivation of patient-specific neurons from somatic cells are emerging as powerful in vitro tools to
investigate the intrinsic cellular pathological behaviours of the diseases that aﬀect these patients. While the use of patient-derived
neurons to model Parkinson’s disease (PD) has only just begun, these approaches have allowed us to begin investigating disease
pathogenesis in a unique way. In this paper, we discuss the advances made in the field of cellular reprogramming to model PD and
discuss the pros and cons associated with the use of such cells.
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder for
which there is currently no disease modifying treatment but
a number of symptomatic therapies. The disease is clinically
defined by its motor features, which include rigidity, bradyki-
nesia, resting tremor, and postural and gait disturbances. PD
patients are also aﬀected by a variety of nonmotor deficits
such as hyposmia, autonomic dysfunction, sleep distur-
bances, cognitive impairment, and psychiatric symptoms [1].
The core pathology is the loss of dopaminergic neurons of the
substantia nigra, although many other neuronal populations
are also aﬀected including the noradrenergic locus coeruleus,
serotoninergic raphe nucleus, and cholinergic basal forebrain
systems as well as range of other structures such as the cortex,
olfactory bulb, and even the enteric nervous system. Whilst
the loss of the dopaminergic nigrostriatal pathway is the
classical biochemical deficit in PD, pathologically it is the
formation of Lewy bodies. Lewy bodies are composed of
insoluble protein aggregates mainly made up of the protein
α-synuclein (α-syn).
While this summary is a useful starting point in our
understanding of PD, it is only an approximation of the true
nature of this disorder as the disease is now recognised to
be very heterogeneous at both the clinical and pathological
levels [2]. Therefore, better classifying subtypes of PD will be
necessary as will be the need to understand the diﬀerences in
disease pathogenesis at the cellular and systems levels in these
diﬀerent forms of PD.
One approach, which holds great promise in terms
of dissecting the diﬀerent cellular events underlying the
genesis of diﬀerent subtypes of disease, is the area of
cellular reprogramming of somatic cells from PD individ-
uals themselves. Following the seminal demonstration that
diﬀerentiated human somatic cells could be reprogrammed
into a pluripotent state by the overexpression of a set of
defined transcription factors (Oct4, Sox2 with either the
combinations of Klf4 and Myc or Nanog, and Lin28) [3–5],
the door to a whole new field of research has been opened.
This technology using induced pluripotent stem (iPS) cells
allows for cells to be grown from patients themselves which
have
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(1) the capacity to proliferate indefinitely in culture;
(2) a pluripotency profile, such that they can in theory
be diﬀerentiated into any cell type, including neurons
and more specifically dopaminergic nerve cells. iPS
cells thus hold great promise for the in vitromodeling
of neurodegenerative disorders, including PD.
More recently, it has been shown that one can actually di-
rectly reprogram human somatic cells into neurons, thereby
avoiding the pluripotent state. This is also another emerging
alternative approach to study patient-specific pathological
disease processes. These reprogrammed cells could also be
extremely useful for screening potential compounds for
therapeutic purposes.
Since the first reports on human iPS cells and induced
neurons (iN) were published, the field has moved forward at
great speed, and in this paper, we present the highlights of
the field as well as where it is going in terms of therapeutic
applications.
2. Modeling PDwith iPS Cells
iPS cells derived from patients oﬀer a powerful in vitromodel
to study disease as these cells carry the necessary genetic risk
factors for that disorder. The first iPS cells generated from PD
patients were derived from fibroblasts harvested from skin
biopsies and provided the first opportunity to truly study
human pathological processes and drug development in vitro
[6].
One of the first studies to successfully produce midbrain
dopaminergic neurons from mouse iPS cells obtained neu-
rons that expressed a number of markers specific to the
midbrain dopaminergic system such as Nurr1, Pitx3, and
tyrosine hydroxylase (TH) and had an electrophysiological
pattern characteristic of nigral dopaminergic neurons [7].
Subsequently, human iPS cells were also eﬃciently diﬀeren-
tiated into committed neural stem cells and dopaminergic
neurons (iDA) using identical diﬀerentiation protocols to
those used for human embryonic stem (ES) cells. Using such
protocols, 30% TH diﬀerentiation was achieved, and the
functionality of these neurons was further demonstrated by
iDA survival with improvements in behavioral deficits when
they were grafted into 6-hydroxydopamine- (6-OHDA-)
lesioned rats [8]. Other groups have now further refined
the diﬀerentiation protocol to obtain a more reliable and
eﬃcient production of iDA by either modulating FGF/ERK
signaling [9] or by genetic engineering iPS cells with
lentiviral vectors regulating the expression of Lmx1a [10].
At least 10 subtypes of dopaminergic neurons exist in the
adult brain (A8–A17) [23], all of which show specific elec-
trophysiological, neurochemical, and transcriptional pro-
files [24–26]. Ventral midbrain dopaminergic neurons—
especially those found in the substantia nigra—are those
most vulnerable to degeneration in PD [27, 28], and it
is known that these A9 nigral dopaminergic neurons are
needed in cell transplants to restore function in animal
models of PD [12, 29–31]. If we hope to use iN to model
PD, it is imperative that these neurons are genuine human
midbrain nigral neurons.With this inmind, a human iPS cell
diﬀerentiation protocol targeting both early dorsalizing and
ventralizing neural patterning pathways has been proposed
[12]. Using this protocol, diﬀerentiated cells expressed all of
the relevant markers, although electrophysiological studies
were not performed which limits what one can say about
these cells.
Several groups have now been able to produce PD
patient-specific iDA derived from iPS cells. The first of these
used fibroblasts from idiopathic PD patient and showed that
iDA derived from iPS cells, regardless of the underlying dis-
ease or the age of the donor, did not show any disease-related
phenotype [11]. This particular study also highlighted that
residual transgene expression in virus-carrying iPS cells
influenced their molecular properties and recommended
that derivation methods free of reprogramming factors
should be used.
This led to the first proof of concept study in which
iDA derived from iPS cells from sporadic and LRRK2-
associated PD patients displayed distinct disease-specific
pathology [13]. In contrast, Soldner and colleagues [11]
found no diﬀerences between the iDA from PD patients and
controls in any measure after 30 days in culture. In their
study, the majority of iN expressed the ventral midbrain
dopaminergic neuronal phenotype, as compared to only 10%
in the previous reports [11, 13]. However, time in vitro may
have been amore critical factor here, as the long-term culture
(<75 days) of iDA derived from sporadic PD cases revealed
an altered morphology in PD-iDA, in particular, a decrease
in the number and length of neurites and an increased
susceptibility to degeneration and defective autophagosome
clearance [13].
While the vast majority of PD cases are idiopathic
(>85%), several causative genes have been identified in
families displaying Mendelian inheritance of the disorder
[32]. As a result, one obvious application of iDA is to
study dopaminergic neuronal behavior associated with these
genetic mutations. Thus far, four PD-related genes have been
studied using iPS cell technology: SNCA, Leucine-rich repeat
kinase 2 (LRRK2), phosphatase and tensin homolog (PTEN)-
induced putative kinase 1 (PINK1), and Parkin (Table 1).
2.1. SNCA. Alpha SNCA is the gene coding for α-syn, the
main component of Lewy bodies [33]. It was also the
first gene with mutations identified to cause autosomal
dominant PD. Thus far, four diﬀerent missense mutations
(A53T, A30P, E46K, and H50Q) have been linked to
familial PD, as well as duplications and triplications of the
entire gene [34, 35]. So far, iPS cell lines from patients
carrying a triplication of SNCA have been generated and
diﬀerentiated into iDA [16]. While the fibroblasts did
not express α-syn, a two fold increase in α-syn mRNA
and protein expression was reported in patient-derived
iDA when compared to cells from unaﬀected first-degree
relatives sharing a similar genetic background. This provides
the first proof-of-principle that this type of approach is
viable to study Mendelian genetically driven pathological
processes involved in α-synucleinopathies. However, given
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Table 1: Summary of studies that have used dermal fibroblasts from PD patients to model the disease.
Forms of PD
Source of
cells
Main findings References
Sporadic
Dermal
fibroblasts
↓
PD-specific iPS cells are able to generate dopaminergic neurons
[11]
iPSC New human iPS cell diﬀerentiation protocol to produce vmDA neuron
[12]
↓
iDA
Morphological alterations (reduced numbers of neuritis and neurite
arborization), accumulation of autophagic vacuoles
[13]
Dermal
fibroblasts
↓
iDA
Rapid and eﬃcient induction of iDA from human PD patient fibroblasts [14]
Familial
SNCA triplication
Dermal
fibroblasts
↓
Accumulation of α-syn, inherent overexpression of markers of oxidative
stress, and sensitivity to peroxide induced oxidative stress
[15]
SNCA triplication iPSC
Production of double the amount of α-syn as neurons from the unaﬀected
relative
[16]
SNCA A53T mutation
↓
iN/iDA
Successful genetic repair of the mutation [17]
LRRK2 G2019S
mutation
Dermal
fibroblasts
↓
Increased expression of key oxidative stress-response genes and α-syn
protein. Increased sensitivity to caspase-3 activation and cell death caused
by exposure to stress agents
[18]
LRRK2 G2019S
mutation iPSC
Morphological alterations (reduced numbers of neurites and neurite
arborization), accumulation of autophagic vacuoles
[13]
LRRK2 G2019S,
R1441C mutations
↓
iDA
Vulnerability associated with mitochondrial dysfunction which could be
rescued with coenzyme Q10, rapamycin, and the LRRK2 inhibitor GW5074
[19]
Parkin mutation
Increased transcription of monoamine oxidases and oxidative stress,
reduced DA uptake and increased spontaneous DA release
[20]
PINK1 mutation
Dermal
fibroblasts
↓
iPSC
iDA
Impaired recruitment to lentivirally expressed parkin to mitochondria,
increased mitochondria copy number, upregulation of PGC-1α; corrected
by lentiviral expression of wild-type PINK1
[21]
PINK1 Q456X
mutation
Vulnerability associated with mitochondrial dysfunction which could be
rescued with coenzyme Q10, rapamycin, and the LRRK2 inhibitor GW5074
[19]
Risk gene
Glucocerebrosidase
Dermal
fibroblasts
↓
iPSC
↓
iDA
Dramatic increase in α-syn protein levels with accumulation of α-syn,
which results in neurotoxicity through aggregation dependent mechanisms
[22]
Abbreviations: α-syn: α-synuclein; DA: dopamine; iDA: induced dopaminergic neurons; iPS: induced pluripotent stem; LRRK2: Leucine-rich repeat kinase
2; PD: Parkinson’s disease; PGC-1α Peroxisome proliferator-activated receptor-γ coactivator 1α; SNCA: α-synuclein gene; vmDA: ventral mesencephalon
dopaminergic.
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the significant variability of clonal variation and eﬃciency
of diﬀerentiation, this study also highlights the importance
of generating multiple iPS cell lines from a single individual
to identify clones with the capacity to diﬀerentiate into cell
type of interest and also to compare neuronal cultures with
equivalent diﬀerentiation eﬃciency [35].
A subsequent study to diﬀerentiate iPS cell lines into
neurons from patients carrying a triplication of SNCA has
further reported an accumulation of α-syn, overexpression
of markers of oxidative stress, and increased sensitivity to
peroxide-induced oxidative stress [15]. These findings sug-
gest that these features are, at least in part, cell autonomous
and that this approach with iPS cells can be a valuable way
to study pathophysiological processes in the relevant cells
from patients with specific genetic abnormalities. In this
study, both TH-positive and TH-negative neurons exhibited
ubiquitinated intracellular inclusions [15], indicating that
patient-derived iPS cells with SNCA triplication can also be
used to investigate selective vulnerabilities across neuronal
subtypes associated with overexpression of wild-type α-syn.
One of the main considerations in modelling diseases
by iPS cells in vitro includes the diﬃculty in distinguishing
subtle disease-relevant phenotypic changes and how relevant
these are to what takes place in the patients aging central
nervous system (CNS). The lack of genetically matched
controls combined with the high variability of the biological
characteristics of the cells and cell lines derived from a single
healthy donor are also important hurtles [11, 36, 37]. In an
attempt to overcome these obstacles, Soldner and colleagues
(2011) generated human iPS cell lines from patients carrying
the A53T (G209) mutation in the SNCA gene which they
then corrected using zinc finger nuclease-mediated genome
editing [17]. They further confirmed the loss of expression
of the A53T mutated transcript and demonstrated that this
genetic repair did not compromise the ability to diﬀerentiate
into iDA. By so doing, they generated iDA that diﬀered only
in this gene (i.e., a gene which gives the cell its susceptibility
for PD), providing genetically matched control cells to
study the eﬀects of that specific mutation. However, while
this approach is appealing to study cellular mechanisms
associated with Mendelian forms of PD, it excludes the use of
iPS cell lines to investigate idiopathic PD as such mutations
do not exist.
Intracellular protein interactions relevant to PD have
also been tackled using iDA reprogrammed from iPS cells
derived from patients carrying a mutation in the glucocere-
brosidase gene. This mutation is known to alter sphingolipid
metabolism and has also been linked to parkinsonism [38].
Indeed, it has been suggested that there is a bidirectional
eﬀect of α-syn and glucocerebrosidase which acts to form
a positive feedback loop that leads to a self-propagating
disease. Namely, the glucocerebrosidase mutations jeopardize
lysosomal protein degradation leading to aggregation of
α-syn and neurotoxicity. Conversely, in iDA with wild-
type glucocerebrosidase, α-syn inhibits lysosomal activity,
suggesting that a loss of glucocerebrosidase in some patients
with PD and a glucocerebrosidase heterozygote mutation
could catalyse α-syn aggregation and by so doing contribute
to the pathogenesis of their PD [22].
2.2. LRRK2. Mutations in the LRRK2 gene have been
reported to be the most frequent cause of late-onset auto-
somal dominant, as well as sporadic, PD [39, 40]. How-
ever, these mutations give rise to inconsistent pathological
features, ranging from Lewy body inclusions to a strictly
nigral degeneration with an absence of Lewy bodies [41].
LRRK2 is a kinase with many domains which is capable
of controlling many protein-protein interactions. While it
is thought that changes in LRRK2 protein domains can
influence kinase activity by interfering with other proteins
[42], the mechanism underlying the pathogenesis of LRRK2-
PD patients is currently unknown. Studies of iPS cells
derived from a single patient carrying the G2019S mutation
in the LRRK2 gene demonstrated increased accumulation
of α-syn, an upregulation of key oxidative stress response
genes and a selective vulnerability of TH-positive iN to
neurotoxins, including H2O2, MG-132, and 6-OHDA [18].
As for iDA derived from sporadic PD cases, Sa´nchez-Dane´s
and colleagues (2012) have reported that long-term cultures
of iDA carrying a LRRK2 mutation displayed abnormal mor-
phology, defective autophagosome clearance, and increased
susceptibility to degeneration. Consistent with previous
findings, aberrant diﬀuse cytoplasmic accumulation of α-syn
in iDA diﬀerentiated from these LRRK2-PD iPS cells was also
observed when compared to both control and idiopathic PD-
derived iPS cells [13]. Furthermore, iN derived from patients
carrying either the homozygous G2019S or the heterozy-
gous R1441C show that while the mitochondrial electron
transport chain is intact, these cells exhibit a neuronal cell
type-specific increased sensitivity to mitochondria chemical
stressors that depolarize mitochondria using K+ ions but not
protons (H+) [19]. This suggests that LRRK2 is involved in
the cell ability to respond to mitochondria damaged by the
influx of K+ ions.
2.3. Parkin and PINK1. Mutations in the parkin gene are
a cause of autosomal recessive PD, which usually manifests
early in life. Indeed, homozygous mutations in parkin are the
most frequent causes of juvenile PD. This early onset form of
the disease is characterized by nigral neuronal loss and gliosis
but rarely has Lewy bodies. The Parkin protein functions
as an E3 ubiquitin ligase to conjugate ubiquitin proteins to
lysine residues of target proteins [43].
PINK1 is a mitochondrial kinase for which pathogenic
mutations are the second most common cause of autosomal
recessive early onset PD [44]. Loss-of-function mutations in
the gene are thought to either compromise the kinase activity
of PINK1 or interfere with its protein stability [45, 46].
Both Parkin and PINK1 are involved in mitochondrial
function [47], and PINK1 has been suggested to func-
tion upstream of Parkin [48–50]. Midbrain iDA repro-
grammed from iPS cells derived from skin fibroblasts of PD
patients with parkin mutation exhibit increased spontaneous
dopamine release and uptake, as well as an elevation
in reactive oxygen species production. Of note, lentiviral
expression of parkin, but not its PD-linked mutant, rescues
these phenotypes. However, mitochondria are not seemingly
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aﬀected in these cells and the levels of TH and α-syn expres-
sion are not diﬀerent when compared to cells from control
subjects. [20]. In contrast, a further study showed that
in human iDA carrying an endogenous PINK1 mutation,
Parkin did not translocate to mitochondria, suggesting that
mutations in PINK1 result in diminished recruitment of
Parkin. This impairment was abrogated by the expression of
normal PINK1. In addition, as opposed to wild-type iDA,
mitochondrial DNA did not decrease in depolarized mutant
PINK1 iDA [21].
As it has been demonstrated for LRRK2 mutations, iN
cells carrying a recessive homozygous Q456X PINK1 muta-
tion show an impaired capacity to respond to mitochondria
damaged by the influx of K+ ions. These cells are also less
able to respond to oxidative stress. Vulnerability to chemical
stressors could be rescued by the antioxidant coenzyme
Q10 and a LRRK2 inhibitor, but not rapamcyin [19]. This
suggests that the increased production of ROS induced by
the loss of PINK1 could be associated with LRRK2 functions.
While a relatively small amount of studies employing iPS
cells from PD patients harboring a genetic mutation have
been performed, they have been instrumental in clarifying
some of the roles of critical proteins underlying familial
forms of PD and their interactions with one another. These
studies can further provide clues on how to tackle cell-
autonomous pathological mechanisms in relevant neurons
from idiopathic PD patients who represent the vast majority
of cases. However, they are not able to investigate how
diﬀerent cellular compartments (e.g., glial cells) may interact
in the overall disease process.
3. Modelling PDwith Direct
Neuronal Conversion
In recent years, neurons diﬀerentiated from iPS cells have
provided new insights into the cellular mechanisms involved
in the pathophysiology of PD. However, concerns remain
with respect to their utility to do this given that they
are reprogrammed back to a more pluripotent stage. To
overcome this issue, several groups have developed methods
that allow direct conversion of human diﬀerentiated somatic
cells, such as fibroblasts, into functional neurons avoiding a
pluripotent state.
The first proof-of-concept study was achieved by the
conversion of mouse embryonic and postnatal fibroblasts
into functional neurons by the overexpression of three
transcription factors (Ascl1, Brn2, and Mytl1). These iN
displayed neuronal properties such as the generation of
action potentials as well as synapse formation [51]. Human
fibroblasts have also been successfully converted into func-
tional neurons by overexpressing the same transcription
factors [52]. Several subsequent studies have been under-
taken with the aim of optimizing these conversion methods.
For example, functional neurons have been generated using
two of the aftermentioned factors (Brn2 and Mytl1) with
the addition of a microRNA (miR-124) [53] or with the
combination of microRNAs (miR-124 and miR-9/9∗) and
NeuroD2 [54]. While these methods generated cells that
exhibited both electrophysiological and morphological char-
acteristics typical of neurons, their neuronal subtype identity
remained unclear.
The ability to convert human fibroblasts into functional
glutamatergic forebrain neurons has been shown with cells
from Alzheimer’s disease patients, using a combination of
four transcription factors (Ascl1, Brn2, Mytl1, and Zic1)
[55]. The addition of two further transcription factors
specific for the dopaminergic lineage (Lmx1a and FoxA2)
is also suﬃcient to generate cells expressing TH and a do-
paminergic morphology with a 10% conversion eﬃciency
[52]. Furthermore, the reduction of this combination of
transcription factors to only three (Ascl1, Nurr1, and
Lmx1a) was suﬃcient to obtain cells with a dopaminergic
neuronal-like morphology and appropriate electrophysio-
logical properties [14]. However, the gene expression profiles
of these reprogrammed DA neurons diﬀered significantly
from primary midbrain DA neurons in these studies, and
so more recent attempts to generate iDA-like midbrain
dopaminergic neurons have used six reprogramming factors
(Ascl1, Pitx3, Nurr1, Lmx1a, Foxa2, and En1), as well as the
patterning factors Shh and FGF8 [56]. The iDA so generated
expressed the generic dopaminergic markers TH, dopamine
transporter (DAT), aromatic L-amino acid decarboxylase
(AADC), and vesicular monoamine transporter 2 (VMAT2)
and were also shown to release dopamine but only partially
restored dopamine system functions in vivo in animal models
of PD. These iDA cells also failed to show similar levels of the
relevant transcription factors when compared to embryonic
or adult midbrain dopamine neurons [56]. More recently,
a combination of five transcription factors (Ascl1, Pitx3,
Nurr1, Sox2, and Ngn2) generated iDA that were able to
better reverse deficits when grafted into the 6-OHDA rat
model of PD, suggesting that these reprogrammed cells dis-
play more properties of functional midbrain dopaminergic
neurons [57].
Because the direct conversion does not go through a
proliferative state, the quantity of neurons that can be
obtained is limited by the accessible number of fibroblasts
used as starting material for conversion. Nevertheless, direct
conversion of patient’s fibroblasts into relevant neuronal
subtypes is very promising for disease modeling as well as
potentially being useful for autologous cell therapy.
4. iDA as a Cell Therapy Source for
Grafting in PD
Cell therapy is one of the promising experimental therapeutic
approaches currently being tested in the clinic in patients
with PD. However, ethical and logistical issues associated
with the use of human fetal tissue prevent the widespread
adoption of these cells in the clinical setting. The use of ES
cells has been proposed as an alternative, mainly because
these cells have the potential to generate all type of cells and
provide an unlimited source of donor tissue [58]. However,
the use of these cells has been hampered by (i) ethical issues,
(ii) their tumourigenic potential; (iii) their ability to generate
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suﬃcient numbers of true nigral dopaminergic neurons;
(iv) the possible immune rejection of them due to host-
donor immunological incompatibilities. Thus eﬀorts have
been made towards developing protocols that result in large
numbers of nigral dopaminergic neurons, in the absence of
any proliferative cell type or immune reaction to them.
iDA generated from iPS cells derived from the skin
fibroblasts of patients are very appealing in this respect.
Indeed, do these cells circumvent not only ethical issues
associated with the use of fetal tissue, but also the risk of
immune rejection. One other benefit in using iPS cells is
the possibility of rejuvenating the cells from an aged patient
and thus eliminating the pathologies associated with aging
including the risk of Lewy body pathology in the transplant.
This potential for iDA derived from iPS cells to be used
as a cell replacement therapy has been assessed in the 6-
OHDA rat model of PD. Studies have shown that grafted iPS
cells functionally integrate into the host brain, and a large
proportion of them diﬀerentiate into dopaminergic neurons
expressing relevant markers such as TH, En1, VMAT2, and
DAT four weeks following grafting [7]. While the vast major-
ity of grafted animals showed behavioral improvements [7],
continuous proliferation of transplanted cells, reminiscent of
teratomas, was observed in some cases, and this raises serious
safety concerns with their use [7, 59]. Diﬀerentiated iN and
iDA have also been grafted in the 6-OHDA lesioned rat. Here,
it has been shown that a small proportion of iN send out
nondopaminergic connections into the surrounding white
matter and that the iDA themselves had TH+ fibers that
projected more within the graft than the host striatum
[60]. These grafted cells did though provide a degree of
functional recovery in amphetamine and apomorphine-
induced rotational asymmetry in the majority of animals but
failed to show improvement in behavioral tests that rely more
on the connectivity of iDA with the host striatum, such as the
cylinder test and the adjustment stepping test [60].
Moreover, several subpopulations of iDA were found
within the graft, including a small number of forebrain- and
hippocampal-like DA neurons. Transplantation of diﬀerenti-
ated cells did not, though, generate teratomas.
Directly converted iDA from fibroblasts have also been
transplanted into 6-OHDA lesioned rodents [56, 57].
Grafted mouse midbrain-like iDA, reprogrammed from
tail tip fibroblasts, maintained their neuronal morphology,
extended TH+ fibers into the host striatum, generated a
rise in local dopamine levels and improved amphetamine-
induced rotational behavior two months posttransplanta-
tion [56]. Human iDA also retained their dopaminergic
neuron-like properties in vivo for up to 4 months post-
transplantation [57].
Several proof-of-concept studies have thus been under-
taken to show the capacity of iPS cells and iDA to provide
functional recovery in toxin-induced animal models of PD.
However, a number of questions remain to be answered such
as the following.
Do these cells really form mature nigral dopaminergic
neurons with their characteristic axonal outgrowth and
arborisation?
How safe are these cells when used in this way?
Do these cells retain disease-specific vulnerability that
will adversely aﬀect their long-term beneficial eﬀects?
In the case of Mendelian forms of PD, can we repair
disease-related mutations in vitro and transplant corrected
cells?
Can these cells be reprogrammed to replace all the cell
losses seen in this disease?
5. Advantages and Limitations of
the Use of Fibroblast-Derived Cells to
Mimic PD Pathology
iPS cells have enormous potential for better understanding
and treating PD but they also present a number of problems,
some of which, but perhaps not all, will be resolved as the
technology evolves. The clear advantage of using iDA derived
from skin fibroblasts is that these cells are patient-specific,
primary human cells which are easily available and relatively
easy to culture. These cells thus provide multiple possibilities
in the field of personalized medicine, with the potential for
drug screening/testing on a range of aﬀected neuronal cell
populations.
There are also concerns with the use of iPS cell tech-
nology to study age-related pathologies such as PD. The
induction of pluripotency is accompanied with a progressive
elongation of telomeres with passaging [61–64], thus rejuve-
nating the cells in a similar way to the embryonic stem cell
state, even in cells derived from aged individuals. However,
the telomere chromatin returns to a mature state, similar
to the one they were originally in when harvested, when
diﬀerentiated again. iPS cells also retain DNA methylation
patterns that are indicative of their original state before
derivation [65–67]. The use of diﬀerentiated cells derived
from iPS cells to model PD can be hampered by aberrant
chromatin formation at the telomere level or elsewhere,
making them more predisposed to telomere shortening
and/or malignant transformation [68]. Going through the
iPS cell stage creates reprogrammed iN that could be
too young to exhibit PD phenotypes, and it has been
suggested that it may therefore be necessary to accelerate PD-
related phenotypes with exogenous stressors such as in vitro
exposure to oxidative stress, neurotoxins, or overexpression
of PD-associated proteins [11]. In this respect, longer culture
times maybe all that is necessary, and indeed it has been
shown that with iDA, the expression of these phenotypes
does occur with increasing time in culture [13].
One other challenge that has to be overcome when
modelling diseases using somatic cells as a primary source
is the variable biological characteristics of cells from healthy
donors as controls. Aspects that can vary include diﬀerences
in genetic background, as well as in the cell derivation
and diﬀerentiation processes [11, 36, 37], along with the
genetic alterations introduced during the reprogramming
process [69, 70]. Finally, whether human iPS cells are ever
truly equivalent to the cell type into which they are being
reprogrammed at the molecular and functional levels is
another question that still needs to be answered [71].
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Several major obstacles still remain to be overcome
before the use of iPS therapy can be routinely performed in
the clinic. Safety is a large concern, as these cells should be
free from genetic aberrations and capable of diﬀerentiating
into fully committed cells. A better understanding of the gene
profiling that guides their development and diﬀerentiation
would allow for the development of newer, safer techniques
for human iPS cell derivation. Moreover, understanding the
best approach to evaluate the properties of human iPS cell-
derived diﬀerentiated cells and compare them with their
natural counterparts in vivo will be critical in this regard.
While exogenously used factors can be turned oﬀ during
and after reprogramming, the possibility that they could
either be turned back on during diﬀerentiation or that
they could integrate and aberrantly activate oncogenes still
exists. Although much work is therefore needed to optimize
reprogramming methods and ensure a safe and eﬃcient
means of neuronal derivation, as well as their detailed cellular
behavior, researchers have been increasingly hopeful that iPS
cells or iDA will be a source of cells for studying disease
pathogenesis as well as possibly cell replacement therapy in
PD.
6. Somatic Cells for Future
Alternative PDModelling
PD is a complex disorder involving multiple systems and
various cell types, including both neurons and glia. The
ability to model PD using the conversion of somatic cells
from PD patients would therefore benefit from the develop-
ment of cocultures of multiple induced cell lineages. Aside
from iDA, successful diﬀerentiation into neuronal subtypes
includes glutamatergic neurons [72–74], GABAergic neurons
[75], and motorneurons [76, 77]. Diﬀerentiation into an
astrocyte lineage has been demonstrated with human iPS
cells [78–83], although these cells represent only a small
proportion of the total neural cells in culture. A recent study
has induced neural stem cells from mouse fibroblasts using
a shorter version of the reprogramming protocol, and these
cells retained the capacity to diﬀerentiate into the three main
neural lineages neurons, astrocytes, and oligodendrocytes
[84]. Human iPS cells derived from fetal fibroblasts can
also be diﬀerentiated into endothelial cells and recapitulate
angiogenesis both in vitro and in vivo [85]. While microglia
have been generated from mouse embryonic stem cells [86]
and lineage-negative bone marrow cells from adult mice
[87], successful reprogramming of somatic cells, such as
fibroblasts into this cell type, has yet to be reported.
Studying the cellular pathology of diﬀerent cell types
could unravel their role in disease processes and by so doing
help in the development of better therapeutic approaches.
For example, in addition to iN reprogrammed from iPS
cells derived from Huntington’s disease patients that display
changes in electrophysiology, metabolism, cell adhesion, and
cell vulnerability to stressors [88], induced astrocytes exhibit
cytoplasmic empty vacuoles [89], an abnormal phenotype
that has been observed in peripheral blood lymphoblasts
harvested from Huntington’s disease patients [90]. While the
role of these vacuoles is not known, these findings underline
the importance of assessing disease-specific phenotypes
within each cell type involved in the pathophysiology of the
disease. Furthermore, the establishment of an in vitro system
in which multiple types of cells aﬀected in PD could coexist
would clearly provide additional information as to how they
interact within the PD brain to generate the disease state.
7. Conclusions
Because iPS cells and directly converted cells from fibroblasts
circumvent many of the ethical considerations that surround
the use of ES cells, as well as originating from the patient
themselves, they oﬀer a wide range of possibilities for
mainstream clinical use across the globe. One promising
therapeutic application would be to generate iPS cells from
patients that have genetic diseases, repair the genetic defect,
diﬀerentiate the cells into the desired phenotype, and then
reintroduce them into the patient. These cells could also
be helpful in vitro in identifying new pathogenic pathways
as well as novel biomarkers for individuals at risk of
developing PD or complications of it (e.g., PD dementia).
While a tremendous amount of work is still needed to
reach these goals, the derivation of iPS cells from both
familial and idiopathic PD patients to model the disease
in vitro uniquely allows for therapeutic cell manipulations
that cannot be performed in vivo. This will ultimately
define in diﬀerent subgroups of patients whether a given
mutation or more complex gene interaction provides a
cellular vulnerability or whether the disease process requires
additional environmental or epigenetic factors. Although still
in its infancy, the diversity of applications associated with the
use of iPS and directly converted cells from fibroblasts makes
this field of research one of the most promising for the in
vitromodeling of PD and through this, the derivation of truly
novel therapeutic approaches.
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